Cooper Financial Group Increases Vertex Pharmaceuticals Stake

Firm adds 3,021 shares to its Vertex Pharmaceuticals holdings in Q4 2025

Mar. 22, 2026 at 8:22am

Got story updates? Submit your updates here. ›

Cooper Financial Group increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 130.2% during the fourth quarter of 2025, according to the company's disclosure with the Securities and Exchange Commission. The fund now owns 5,341 shares of the pharmaceutical company's stock, worth $2.42 million at the end of the reporting period.

Why it matters

Vertex Pharmaceuticals is a leading biotechnology company focused on developing treatments for serious diseases like cystic fibrosis. The increase in Cooper Financial Group's stake suggests the firm sees long-term growth potential in Vertex's pipeline and commercial products.

The details

Cooper Financial Group added 3,021 shares of Vertex Pharmaceuticals during the fourth quarter, bringing its total holdings to 5,341 shares. This represents a 130.2% increase in the firm's position. Vertex Pharmaceuticals is known for its portfolio of CFTR modulators that target the underlying cause of cystic fibrosis.

  • Cooper Financial Group disclosed the increase in its Vertex Pharmaceuticals holdings in a filing with the SEC on March 22, 2026.

The players

Cooper Financial Group

An investment management firm that increased its stake in Vertex Pharmaceuticals during the fourth quarter of 2025.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Cooper Financial Group's increased investment in Vertex Pharmaceuticals suggests the firm sees long-term growth potential in the biotech company's pipeline and commercial products, particularly its CFTR modulators for cystic fibrosis.